These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18837734)

  • 1. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 3. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Campbell TM; Brown CW
    J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
    Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
    Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib induced target-like purpura.
    Rungtrakulchai R; Rerknimitr P
    Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib-induced scalp perifolliculitis.
    Rallis E; Petronic-Rosic V; Korfitis C
    Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
    Lin TC; Wu PY
    Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
    [No Abstract]   [Full Text] [Related]  

  • 11. Purpuric drug eruption and alopecia induced by erlotinib.
    Nakamura-Wakatsuki T; Yamamoto T
    Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An acneiform eruption due to erlotinib: prognostic implications and management.
    Journagan S; Obadiah J
    J Am Acad Dermatol; 2006 Feb; 54(2):358-60. PubMed ID: 16443077
    [No Abstract]   [Full Text] [Related]  

  • 13. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
    Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
    J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
    [No Abstract]   [Full Text] [Related]  

  • 14. Acneiform reaction to erlotinib.
    Schalock PC; Zug KA
    Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of bullous dermatitis induced by erlotinib.
    Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
    Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib-induced dermatologic side-effects.
    Bovenschen HJ; Alkemade JA
    Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
    Chanprapaph K; Pongcharoen P; Vachiramon V
    Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.